SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
FRA:1SXP - Deutsche Boerse Ag - DE000A3ENQ51 - Common Stock - Currency: EUR
Overall 1SXP gets a fundamental rating of 6 out of 10. We evaluated 1SXP against 15 industry peers in the Life Sciences Tools & Services industry. 1SXP gets an excellent profitability rating and is at the same time showing great financial health properties. 1SXP is not valued too expensively and it also shows a decent growth rate. With these ratings, 1SXP could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
1SXP had a positive operating cash flow in the past year.
1SXP had positive earnings in each of the past 5 years.
In the past 5 years 1SXP always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 9.07%, 1SXP belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
1SXP has a better Return On Equity (16.17%) than 94.12% of its industry peers.
1SXP's Return On Invested Capital of 12.56% is amongst the best of the industry. 1SXP outperforms 94.12% of its industry peers.
1SXP had an Average Return On Invested Capital over the past 3 years of 15.68%. This is significantly above the industry average of 6.82%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.07% | ||
| ROE | 16.17% | ||
| ROIC | 12.56% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
1SXP has a better Profit Margin (14.05%) than 76.47% of its industry peers.
1SXP's Profit Margin has been stable in the last couple of years.
With a decent Operating Margin value of 16.77%, 1SXP is doing good in the industry, outperforming 70.59% of the companies in the same industry.
1SXP's Operating Margin has improved in the last couple of years.
The Gross Margin of 1SXP (33.04%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.77% | ||
| PM (TTM) | 14.05% | ||
| GM | 33.04% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 1SXP is creating value.
The number of shares outstanding for 1SXP remains at a similar level compared to 1 year ago.
The debt/assets ratio for 1SXP is higher compared to a year ago.
2.2 Solvency
1SXP has an Altman-Z score of 5.07. This indicates that 1SXP is financially healthy and has little risk of bankruptcy at the moment.
1SXP has a better Altman-Z score (5.07) than 94.12% of its industry peers.
The Debt to FCF ratio of 1SXP is 2.00, which is an excellent value as it means it would take 1SXP, only 2.00 years of fcf income to pay off all of its debts.
1SXP has a better Debt to FCF ratio (2.00) than 100.00% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that 1SXP is not too dependend on debt financing.
1SXP has a Debt to Equity ratio of 0.10. This is amongst the best in the industry. 1SXP outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 2 | ||
| Altman-Z | 5.07 |
ROIC/WACC1.74
WACC7.2%
2.3 Liquidity
1SXP has a Current Ratio of 1.40. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP has a Current ratio (1.40) which is comparable to the rest of the industry.
A Quick Ratio of 1.06 indicates that 1SXP should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.06, 1SXP is not doing good in the industry: 64.71% of the companies in the same industry are doing better.
1SXP does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
1SXP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.43%.
The Earnings Per Share has been growing by 14.04% on average over the past years. This is quite good.
Looking at the last year, 1SXP shows a small growth in Revenue. The Revenue has grown by 6.51% in the last year.
Measured over the past years, 1SXP shows a quite strong growth in Revenue. The Revenue has been growing by 13.84% on average per year.
EPS 1Y (TTM)-1.43%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-35.57%
Revenue 1Y (TTM)6.51%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%-1.04%
3.2 Future
The Earnings Per Share is expected to grow by 14.33% on average over the next years. This is quite good.
Based on estimates for the next years, 1SXP will show a quite strong growth in Revenue. The Revenue will grow by 9.92% on average per year.
EPS Next Y6.64%
EPS Next 2Y13.94%
EPS Next 3Y14.25%
EPS Next 5Y14.33%
Revenue Next Year5.65%
Revenue Next 2Y8.73%
Revenue Next 3Y9.21%
Revenue Next 5Y9.92%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 25.09, the valuation of 1SXP can be described as expensive.
Based on the Price/Earnings ratio, 1SXP is valued cheaper than 82.35% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 29.35, 1SXP is valued at the same level.
With a Price/Forward Earnings ratio of 19.33, 1SXP is valued on the expensive side.
Based on the Price/Forward Earnings ratio, 1SXP is valued a bit cheaper than the industry average as 64.71% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.10. 1SXP is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.09 | ||
| Fwd PE | 19.33 |
4.2 Price Multiples
1SXP's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. 1SXP is cheaper than 64.71% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1SXP indicates a slightly more expensive valuation: 1SXP is more expensive than 76.47% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 81.78 | ||
| EV/EBITDA | 16.6 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1SXP does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of 1SXP may justify a higher PE ratio.
A more expensive valuation may be justified as 1SXP's earnings are expected to grow with 14.25% in the coming years.
PEG (NY)3.78
PEG (5Y)N/A
EPS Next 2Y13.94%
EPS Next 3Y14.25%
5. Dividend
5.1 Amount
1SXP has a yearly dividend return of 0.63%, which is pretty low.
Compared to an average industry Dividend Yield of 0.79, 1SXP pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.33, 1SXP's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.63% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
16.84% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.84%
EPS Next 2Y13.94%
EPS Next 3Y14.25%
FRA:1SXP (3/7/2025, 7:00:00 PM)
24.84
-0.56 (-2.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners18.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.74B
Analysts70
Price Target27.91 (12.36%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.63% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.84%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.13%
Min Revenue beat(2)-7.26%
Max Revenue beat(2)-3%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-7.26%
Max Revenue beat(4)11.1%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.68%
PT rev (3m)-19.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.9%
EPS NY rev (1m)-3.5%
EPS NY rev (3m)-6.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.98%
Revenue NY rev (1m)-1.7%
Revenue NY rev (3m)-3.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.09 | ||
| Fwd PE | 19.33 | ||
| P/S | 3.92 | ||
| P/FCF | 81.78 | ||
| P/OCF | 20.37 | ||
| P/B | 4.51 | ||
| P/tB | 4.68 | ||
| EV/EBITDA | 16.6 |
EPS(TTM)0.99
EY3.99%
EPS(NY)1.29
Fwd EY5.17%
FCF(TTM)0.3
FCFY1.22%
OCF(TTM)1.22
OCFY4.91%
SpS6.34
BVpS5.51
TBVpS5.3
PEG (NY)3.78
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.07% | ||
| ROE | 16.17% | ||
| ROCE | 15.36% | ||
| ROIC | 12.56% | ||
| ROICexc | 12.85% | ||
| ROICexgc | 13.25% | ||
| OM | 16.77% | ||
| PM (TTM) | 14.05% | ||
| GM | 33.04% | ||
| FCFM | 4.79% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexcg growth 3Y-8.59%
ROICexcg growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score4
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 2 | ||
| Debt/EBITDA | 0.35 | ||
| Cap/Depr | 200.28% | ||
| Cap/Sales | 14.45% | ||
| Interest Coverage | 12.9 | ||
| Cash Conversion | 80.21% | ||
| Profit Quality | 34.1% | ||
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z | 5.07 |
F-Score4
WACC7.2%
ROIC/WACC1.74
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.43%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-35.57%
EPS Next Y6.64%
EPS Next 2Y13.94%
EPS Next 3Y14.25%
EPS Next 5Y14.33%
Revenue 1Y (TTM)6.51%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%-1.04%
Revenue Next Year5.65%
Revenue Next 2Y8.73%
Revenue Next 3Y9.21%
Revenue Next 5Y9.92%
EBIT growth 1Y11.34%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year55.51%
EBIT Next 3Y29.34%
EBIT Next 5Y21.02%
FCF growth 1Y1205.97%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y24.04%
OCF growth 3Y19.45%
OCF growth 5YN/A